Status and phase
Conditions
Treatments
About
To observe the safety, tolerability and clinical effects of PD-1, chidamide, lenalidomide and gemcitabine in the treatment of newly diagnosed and relapse/refractory peripheral T-cell lymphoma.
Full description
Patients with peripheral T-cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully with the conventional CHOP regimen. The investigators have been proceeding this trial to evaluate the efficacy and safety of the PD-1, chidamide, lenalidomide and gemcitabine in the treatment of newly diagnosed and relapse/refractory peripheral T-cell lymphoma.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
100 participants in 2 patient groups
Loading...
Central trial contact
Mingzhi D Zhang
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal